The nerve damage occurring as a consequence of glucose toxicity in diabetes leads to neuropathic pain, among other problems. This pain dramatically reduces the quality of life in afflicted patients. The progressive damage to the peripheral nervous system is irreversible although strict control of hyperglycemia may prevent further damage. Current treatments include tricyclic antidepressants, anticonvulsants, and opioids, depending on the severity of the pain state. However, available therapeutics have drawbacks, arguing for the need to better understand the pathophysiology of neuropathic pain and develop novel treatments. Here we demonstrate that stabilization of a class of bioactive lipids, epoxygenated fatty acids (EpFAs), greatly reduces allodynia in rats caused by streptozocin-induced type I diabetes. Inhibitors of the soluble epoxide hydrolase (sEHI) elevated and stabilized the levels of plasma and spinal EpFAs, respectively, and generated dose-dependent antiallodynic effects more potently and efficaciously than gabapentin. In acute experiments, positive modulation of EpFAs did not display differences in insulin sensitivity, glucose tolerance, or insulin secretion, indicating the efficacy of sEHIs are not related to the glycemic status. Quantitative metabolomic analysis of a panel of 26 bioactive lipids demonstrated that sEHI-mediated antiallodynic effects coincided with a selective elevation of the levels of EpFAs in the plasma, and a decrease in degradation products coincided with the dihydroxy fatty acids in the spinal cord. Overall, these results argue that further efforts in understanding the spectrum of effects of EpFAs will yield novel opportunities in treating neuropathic pain.
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analgesic drug | soluble epoxide hydrolase inhibitor | cytochrome P450 | glucose homeostasis | motor depressant R ecent Center for Disease Control data indicates that 23.6 million Americans of all ages have diabetes (http://www.cdc. gov/Features/dsDiabetes/). Diabetic neuropathy will manifest in up to half of the diabetic population as the most frequently encountered secondary condition of diabetes. Estimated care costs exceed $150 billion annually (1, 2) . The nerve dysfunction as a consequence of diabetes is debilitating and can lead to lifethreatening autonomic neuropathy, cardiac diseases, and CNS atrophy (3, 4) . Dying back of distal peripheral nerve fibers because of glucose toxicity and the ensuing spinal sensitization are thought to be the underlying causes of pain (5) (6) (7) (8) (9) . Although hyperglycemia is the initiating cause for diabetic neuropathy, aggressive glycemic control is effective in impeding the progression of neuronal loss and pain, but not in reversing neuropathy (10) . Treatments include tricyclic antidepressants, anticonvulsants, serotonin-norepinephrin reuptake inhibitors, opiates, and recently lidocaine and capsaicin have found wider acceptance as add-on treatments (11, 12) . A survey of patients with peripheral neuropathic disorders including diabetic neuropathy in the United Kingdom indicated that a significant number of them were surprisingly taking nonsteroidal anti-inflammatory drugs (NSAIDs) and selective cox inhibitors, despite the lack of apparent benefit from these drugs for neuropathic indications (13) . Indeed, animal models of diabetic neuropathy are insensitive to NSAIDs (14) . Because of the limited efficacy and side effects of current therapeutics, new agents with novel mechanisms of action are needed to provide more effective pain management. To this end, we investigated the feasibility of a unique approach, stabilization of epoxygenated fatty acids (EpFAs) by inhibiting soluble epoxide hydrolase (sEH, E.C. 3.3.2.10) in a streptozocin (STZ)-induced type I diabetes model of neuropathic pain.
Stabilization of natural EpFAs by inhibition of sEH is antiallodynic and antihyperalgesic in models of inflammatory pain without affecting motor function (15) (16) (17) . EpFAs are produced from parent linoleic (LA), arachidonic (AA), eicosapentaenoic (EPA), and docosahexaenoic (DHA) acids by multiple isozymes of the cytochrome P450 enzymes (18) . These molecules not only have selective and direct antinociceptive effects but also modulate the AA cascade, a major biological pathway (16, 19, 20) . The EpFAs participate in physiological events, such as setting of the vascular tone, and they seem to have more important functions in pathophysiological processes (21) (22) (23) . Stabilization of the EpFAs using sEH inhibitors (sEHI) results in beneficial effects in a number of disease models, demonstrating antihyperalgesic, antiinflammatory, and other effects (15, 21, 24) . EpFAs transcriptionally down-regulate cyclooxygenase-2 in addition to redirecting the flow of AA among the three branches of the cascade (16, 19, 25, 26) . Given that glucose itself can influence nociceptive thresholds, we asked if the antinociceptive effects of inhibiting sEH are independent from affecting the glycemic status of rats (27) . The observed biological activity is surprising in this model of pain, which is insensitive to NSAIDs. The EpFAs and sEHI have a significant control over the AA cascade and modulate nociceptive behavior in response to inflammatory algogens, such as LPS and the prostanoid PGE 2 . Here we demonstrate that EpFAs and sEHI reduce neuropathic pain without decreasing peripheral or central prostanoid levels. Our findings highlight an unexpected property of EpFAs and sEH in regulating nociceptive behavior outside of their roles in the inflammatory processes.
Results
Positive Modulation of EpFAs Is Effective in Blocking Type I DiabetesInduced Neuropathic Pain-Related Behavior. STZ is a commonly used former antibiotic selectively toxic to the insulin-producing β-cells of the pancreas. Consistent with previous observations, STZ treatment of rats led to a dramatic rise in blood glucose levels and decrease in pain thresholds that were 40-50% lower than that before administration of STZ (28) . The efficacy of sEH inhibitors was then tested using three different sensory measures: heat hyperalgesia, mechanical hyperalgesia, and mechanical allodynia (Fig. 1A) . Thermal escape latency was not affected by the sEHI 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA) (IC 50 = 11 nM on recombinant rat sEH), although hyperalgesia and allodynia were largely reduced in a dose-and time-dependent manner ( Fig. 1 A and B) . Although AUDA is a very potent sEH inhibitor, more modern sEH inhibitors have higher oral bioavailablity and have been altered to reduce plasma protein binding, increase water solubility, decrease logP, and circumvent the rapid inactivation of AUDA by β-oxidation and P450 hydroxylation on the adamantine. To test the hypothesis that inhibition of the sEH, rather than a compounddependent effect, is responsible for the observed antinociception, we determined the efficacy of two other structurally different sEH inhibitors with longer plasma half-life. For this purpose we focused on the electronic von Frey assay as a sensitive measure of allodynia. The sEHI, 1-trifluoromethoxyphenyl-3-(1-acetylpiperidin-4-yl) urea (TPAU) (IC 50 = 79 nM on recombinant rat sEH), led to a time-and dose-dependent decrease in pain-related behavior, largely restoring nociceptive threshold in the high-dose groups (3 and 10 mg/kg) (Fig. 1C) . The third structurally different sEHI, 1-(1-methylsulfonyl-piperidin-4-yl)-3-(4-trifluoromethoxy-phenyl)-urea (TUPS) (IC 50 = 9 nM on recombinant rat sEH), was also highly effective in reducing allodynia but, unlike TPAU, elevated the mechanical withdrawal threshold (MWT) of rats above their pre-STZ baseline values ( Fig. 2A) . Thus, TUPS was compared with gabapentin, a standard therapeutic that is commonly prescribed to patients suffering from intense neuropathic pain. TUPS (10 mg/ kg) was more efficacious than a 10-fold higher-dose gabapentin, but displayed comparable efficacy to morphine (3 mg/kg) (Fig.  S1 ). This high efficacy and longer duration of activity of TUPS supports its utility as a probe to investigate EpFAs (29) . To test the hypothesis that sustained inhibition of sEH will attenuate allodynia in a prolonged manner, we monitored the MWT of animals for over 4 d following a single dose of TUPS. Compared with TUPS, gabapentin (100 mg·kg·d), was administered daily for 4 consecutive days to maintain a pain-free status. Notably, TUPS at 10-fold lower dose was equally efficacious to daily repeated injections of gabapentin ( Fig. 2A) . Over the course of this experiment, the MWT of TUPS-treated rats was above the pre-STZ baseline level for at least 48 h, after which the effect gradually diminished. However, even after 96 h these rats had significantly less pain-related withdrawal response compared with their pre-TUPS baseline ( Fig. 2A) (diabetic rat before sEHI vs. 96 h after sEHI treatment, P = 0.04, paired t test). Unlike diazepam, TUPS did not affect sensorimotor performance of rats on a revolving rod with steady speed (Fig. 2B) .
Upon administration, TUPS concentration in blood rose rapidly and for 96 h remained well above the in vitro IC 50 value of 9 nM for TUPS, determined using recombinant rat sEH enzyme (Fig. S2 ). Blood inhibitor levels correlated well with bioactivity (Spearman rank order correlation P = 0.002). Overall, these observations support the hypothesis that inhibition of sEH is effective in reducing diabetes-induced neuropathic pain without affecting gross motor skills.
Acute Inhibition of sEH Does Not Influence Glycemic Status of Type I Diabetic Rats. Hyperglycemia directly affects nociceptive thresholds on rat peripheral nerves and dorsal root ganglia (27) . Similarly, in both type II diabetes patients or in healthy human volunteers, intravenous infusion of glucose significantly decreases pain thresholds (30) . Given that sEH is implicated in β-islet function, we asked if inhibition of sEH changed pain-related behavior by modulating the glycemic status of rats (31, 32) . To investigate the acute effect of inhibiting sEH, glucose metabolism was examined at the same time course as the nociceptive assays. TPAU (3 mg/kg s.c.) was administered 30 min before the metabolic tests in all groups. In the insulin tolerance test, no significant differences between STZ+PEG400 and STZ+TPAU groups were detected (Fig. S3A ). In the glucose tolerance test, both STZ +PEG400 and STZ+TPAU groups (all fasted) showed comparable ability to clear glucose from the peripheral circulation, suggesting that acute sEH inhibition did not alter glucose tolerance (Fig. S3B ). There were no differences between animals treated with either vehicle or sEHI in insulin secretion following glucose administration (Fig. S3C) . Rats that were not diabetic but treated with either vehicle or sEHI did not demonstrate any significant differences in glucose levels in response to insulin or following glucose administration (Fig. S3) . These findings support the hypothesis that the observed antinociception was not related to modulation of the glycemic status of the rats by inhibition of sEH. Rather, these pain-reducing effects are acute and seem to be a direct effect on the sensory nociceptive system. To investigate if treatment with sEHI modulated the levels of bioactive lipids, as would be expected from the mechanism of action of sEH inhibition, the levels of 88 lipid metabolites were analyzed by LC-MS/MS and 26 were found above their limit of quantification (Tables S1 and S2 ). Three groups of rats were analyzed (nondiabetic, type I diabetic, and type I diabetic+sEHI). The same volume of vehicle was administered to the two groups that did not receive sEHI. The metabolites reported here are organized into four lipid classes based on the parent fatty acids; LA, AA, EPA, and DHA. Type I diabetic status did not lead to significant changes in the plasma levels of bioactive lipid metabolites compared with nondiabetic rats (expressed as the ratio of epoxy to dihydroxy fatty acids, epoxide/ diol ratio) ( Fig. 3A and Table S1 ). In the liver, the major suspected source of plasma EpFAs, total cytochrome P450 activity was unchanged in diabetic rats compared with controls, although sEH activity was induced threefold by diabetes. Despite higher activity of sEH in the diabetic rats, the plasma dihydroxy fatty acids were not different from nondiabetic animals ( Fig. 3) . Inhibition of sEH led to significant increases in the plasma epoxide/diol ratio of most parent fatty acid classes compared with diabetic and healthy control rats, consistent with earlier findings (Table S1 ). In contrast to a LPS-elicited acute inflammatory model, in the current neuropathy model, plasma levels of two major prostanoids, PGE 2 and PGD 2 , were not significantly elevated by diabetes and inhibition of sEH did not significantly decrease their levels, demonstrating a distinct mechanism of action ( Fig. 3B ).
In the spinal cord tissue, a drastically different profile of bioactive lipids was observed ( Fig. 3C and Fig. S5 ). In diabetic rats, key proinflammatory cyclooxygenase products were elevated (Fig. 3D ). Only the levels of LA metabolites, particularly leukotoxin, increased with diabetes; AA and DHA metabolite EpFAs remained constant (Fig. S5 ). This finding highlights an unexpected asymmetry in bioactive lipid metabolism, given that not all AA metabolites were similarly elevated. EPA-derived metabolites were below the limit of detection. The levels of sEH degradation product dihydroxy fatty acids from LA, AA, and DHA were largely elevated by diabetes, leading to a significant shift in the spinal epoxide/diol fatty acid ratio in favor of dihydroxy fatty acids (see Fig. S5 for concentrations). This increase was not dependent on changes in sEH activity (Fig. S4 ). Whereas inhibition of sEH ameliorated these changes by normalizing the levels of dihydroxy fatty acids, sEH inhibition was without effect on the spinal levels of prostanoids (Fig. 3D ). The broad changes in lipid mediators demonstrate an imbalance in spinal bioactive lipids with diabetes. This imbalance may contribute to allodynia in these animals. Overall, these findings argue in favor of the hypothesis that antinociceptive mechanisms of sEH inhibition are dichotomous and context-dependent for inflammatory versus neuropathic pain.
Discussion
The cytochrome P450-mediated oxygenation of fatty acids leads to the production of EpFAs, a class of bioactive lipids that have exceedingly short half-lives (33) . Levels of these molecules are regulated by synthesis, degradation, and membrane incorporation (17, 34, 35) . However, preventing their hydrolysis by inhibiting sEH offers advantages because this greatly enhances the in vivo epoxide/diol ratio (17, 24) . A number of biological activities have been attributed to EpFAs; their effects on the functioning of the nervous system are newly described (22, 23, 34) . Initial reports of the antinociceptive effects of inhibiting sEH preceded knowledge about the expression and distribution of cytochrome P450 enzymes and the sEH in the central and peripheral nervous systems, particularly in neurons (36, 37) . Clearly, these components are present in both the CNS and the peripheral nervous system. Even though the EpFAs do not fulfill the criteria of being neurotransmitters, nor are they known ligands for major ion channels, they strongly regulate nociceptive signaling peripherally, in the spinal cord, and possibly in the brain (20, 22) . In this study we characterized the acute effect of inhibiting sEH on type I diabetes-induced mechanical allodynia, which was largely effective in eliminating pain behavior. The efficacy of the sEH inhibitor AUDA on two measures of pain-related behavior is consistent with earlier observations where AUDA reduced inflammation-elicited pain behavior (15) . We pursued this observation using two potent and metabolically stable inhibitors, TPAU and TUPS. Overall, three structurally different inhibitors of sEH reversed or eliminated mechanical allodynia in a dosedependent manner. These effects were time-as well as dosedependent, indicating a specific interaction between the inhibition of sEH and the observed decrease in pain-related behavior. Strikingly, TUPS reduced allodynia at least 10-fold more efficaciously than gabapentin, a calcium channel trafficking disruptor drug prescribed to patients suffering diabetic neuropathy (38) . Moreover, the efficacy of TUPS was longer in duration than gabapentin, which was administered daily to maintain a pain-free state (39) . Compared with TUPS, morphine was more efficacious but produced a higher magnitude of analgesia with a shorter duration of efficacy (Fig. S1) . TUPS, in contrast, did not lead to sedation or sensorimotor impairment. Despite this favorable bioactivity profile in rodents and drug-like physicochemical properties, pharmacokinetics with high area-under-the-curve values in monkey (40) , it remains to be seen if inhibitors of sEH will be efficacious in human and outperform some of the current pain medications prescribed to diabetic patients.
Glucose homeostasis was not altered by acute inhibition of the sEH within the time-scale of these experiments, but nociceptive parameters were improved (i.e., the complete elimination of pain-related behavior). Three important parameters of glucose homeostasis-insulin sensitivity, glucose tolerance, and glucosestimulated insulin secretion-remained unchanged. TPAU did not display changes in metabolic parameters related to glucose homeostasis in either diabetic or healthy rats. It was recently reported that chemical inhibition or targeted genetic deletion of sEH prevented hyperglycemia and promoted insulin secretion (32) . Distinctively, metabolic experiments here were conducted in an acute manner: 30 min following inhibitor administration in rats. In contrast, at least 3 wk were required to observe significant changes in metabolic parameters in sEH −/− or sEH +/+ mice receiving a potent sEH inhibitor following STZ administration. Thus, the acute antiallodynic effects are possibly mediated through a different mechanism.
Notably, the efficacy of TUPS correlated with the plasma levels of this compound between 4 and 96 h following administration. This observation supports the hypothesis that the antinociceptive activity is maintained by sEH inhibitor-mediated stabilization of EpFAs. In the early time points following TUPS administration we observed analgesia, which was not correlated to plasma inhibitor levels. This observation suggests that a threshold level of EpFAs or epoxide/diol ratio needs to be reached to initiate antinociceptive activity and that it is reached before maximal plasma concentration of TUPS. Consequently, a sudden and rapid rise in the epoxide/diol ratio results in an initial strong effect after which (i.e., 4 h) the antinociceptive effect becomes dependent on the plasma level of sEH inhibitor, and thus inhibition of sEH, in a linear manner (Fig. S2C ). These observations also argue that EpFAs have a specific, possibly receptor-mediated mechanism of action. It is possible that in an environment where EpFAs are scarce, even a slight increase in EpFAs may tip the balance toward antinociception.
The plasma levels of EpFAs in diabetic+vehicle and diabetic +TPAU treated rats were investigated using the same dose of TPAU (3 mg/kg) as in metabolic studies and behavioral assays. Although type I diabetes did not elicit major changes in the plasma levels of 13 independent EpFAs, TPAU elevated the levels of these metabolites; the levels of their corresponding dihydroxy metabolites were significantly decreased by sEH inhibition (Table S1 ). Among those decreased, EpFA metabolites of AA, EPA, and DHA possess direct antinociceptive effects peripherally in a model of inflammatory pain (20) . Observed antiallodynic activity corresponded well to enhanced plasma epoxide/diol ratio. A full-scale target engagement study was not intended here. However, highly correlative results on plasma inhibitor, metabolite levels, and the antinociceptive effects indicate a significant level of target engagement. It is plausible that the sEH inhibitors are effective because they elevate the levels of numerous antinociceptive molecules. Given that these EpFAs are directly antihyperalgesic when injected into an inflamed paw, TPAU significantly alters the mean ratio of summed epoxy to dihydroxy fatty acids in diabetic rats, with the exception of EPA metabolites (Kruskal-Wallis one-way ANOVA followed by Dunn's all pair-wise comparison, *P < 0.02). Table S1 displays the identity and detected quantity of the metabolites analyzed from plasma. it is reasonable that a portion of the observed antinociception is mediated through peripheral mechanisms (20) . The mode of action of EpFAs and sEHI in the diabetic neuropathic pain model does not seem to involve their ability to modulate NFĸB and the ensuing down-regulation of COX1/2 because no changes in plasma levels of PGE 2 and PGD 2 are observed (25) . Consistent with this argument, sEHI do not down-regulate induced spinal COX-2 in diabetic rats (Fig. 3D) . Thus, our findings demonstrate that the mechanism of action of sEHI in this rodent model differs from inflammatory models.
In the spinal cord, type I diabetes led to a complex profile of bioactive lipids. Key proinflammatory cyclooxygenase products were elevated, consistent with earlier findings indicating upregulation of the COX-2 gene. Although LA-derived EpFAs were elevated, surprisingly the levels of AA-and DHA-derived EpFAs remained unaffected. In contrast, levels of the dihydroxy fatty acids in general were increased, leading to a significant shift in the ratio of epoxy to dihydroxy fatty acids (Fig. S6) . This change was in the absence of a change in spinal sEH activity, thus may be driven by lipolysis. The asymmetric changes highlight the complexity of spinal regulation of bioactive lipids under pathological conditions. It remains to be seen if the dihydroxy fatty acids are biomarkers of spinal pathology. Spinal tissue levels of EpFAs were also investigated using the more potent and antinociceptive inhibitor TUPS. Inhibition of sEH consistently normalized the ratio of epoxy to dihydroxy fatty acids that was greatly reduced in diabetic animals. This normalization was primarily a result of a significant reduction of dihydroxy fatty acid levels by inhibition of sEH. If dihydroxy fatty acids in the spinal cord have pronociceptive roles, reduction of their levels by sEH inhibition should contribute to sEHI-mediated antinociception. Alternatively, the lack of increase in most spinal EpFAs following sEH inhibition may indicate that the primary site of action of sEH inhibitors in this model is not the spinal cord. TUPS was not only antiallodynic but also analgesic. This level of antinociception observed with TUPS administration is difficult to explain solely by normalization of the spinal ratio of epoxy to dihydroxy fatty acids. Although supraspinal sites of action cannot be ruled out, peripheral antinociceptive effects of EpFAs may have a governing role in this model. Nevertheless, the observed changes in lipid metabolites are indicative of spinal lipid dysregulation in diabetic rats and may correlate to human patients with type I diabetes. Such a dysregulation is likely to influence nociceptive signaling, given the known properties of these bioactive lipids. It remains to be seen if these changes selectively occur in diabetes or if similar dysregulation transpires under other neuropathic conditions. If so, one can then begin to identify lipid biomarkers of painful conditions and target these molecules to reduce pain. Targeting spinal lipid dysregulation may become a valuable strategy for treating neuropathic pain as more selective molecular probes become available. Thus, our findings open a venue for searching and investigating unstudied lipid targets in the spinal cord.
In conclusion, by monitoring changes in bioactive lipids in this type I diabetes model, we demonstrated the presence of dysregulated lipid homeostasis and asymmetric metabolism in the spinal cord. Positive modulation of EpFAs by inhibition of sEH dose-dependently attenuated diabetes-elicited neuropathic pain, although the site of action of EpFAs in this model was not addressed. More importantly, we demonstrated that the antinociceptive effects are acute and occur through a mechanism that is unrelated to regulation of glucose homeostasis. Inhibitors of sEH elevated plasma EpFAs and decreased plasma and spinal dihydroxy fatty acids. The biological effects were well correlated with the changes in lipid metabolites and plasma levels of the inhibitors. We report that the efficacy of sEH inhibitors is superior to that of gabapentin in this rat model of diabetic neuropathy. Despite producing analgesia, the inhibition of sEH did not affect sensorimotor function. Although it is not clear if sEH inhibitors will be efficacious in human patients, our findings in rodent models suggest that inhibition of sEH may become a viable strategy to prevent and alleviate neuropathic pain in diabetes patients.
Materials and Methods
Details of the experimental protocols are given in the SI Materials and Methods.
Diabetic Pain Model, Behavioral and Metabolic Tests, and Treatments. Agematched males Sprague-Dawley rats weighing 250-300 g were obtained from Charles River Laboratories and maintained under standard conditions. All studies were conducted in line with federal regulations and were approved by the Institutional Animal Care and Use Committee at the University of California at Davis. Diabetes was instigated by a single intravenous injection of STZ (55 mg/kg) as described by Aley and Levine (28) . Nociceptive measurements were taken at the same time of the day for all groups. Pain behavior was measured using von Frey, RandallSelitto, and modified Hargreaves' tests (15, 16) . Prediabetic baseline mechanical withdrawal thresholds varied between 70 and 80 g of force for both mechanical tests. The baseline withdrawal thresholds before STZ administration were taken as 100% response and all mean nociceptive thresholds were converted to percentage values. All data are presented as mean ± SE of mean. Glucose was measured in blood collected from the tail using a portable glucometer (Home Aide Diagnostics). Serum insulin was determined by ELISA using rat insulin as a standard (Crystal Chem). Metabolic tests were performed as described in detail in the SI Materials and Methods. Results are expressed as milligram per deciliter of glucose or nanogram per milliliter insulin. Inhibitors were administered after completely dissolving in vehicle PEG400 (1 mL/kg). Oxylipin analysis from plasma and tissues are described in the SI Materials and Methods. Gabapentin and morphine were dissolved in saline. Drugs were administered by subcutaneous or intraperitoneal routes, as specified. Blood samples (∼5 μL) from tail vein were obtained on a daily basis immediately after pain measurements and TUPS was quantified using LC-MS/MS. Statistical Analyses. Data were analyzed by parametric and nonparametric one-way ANOVA followed by post hoc tests, as indicated in the figure legends, using the SigmaPlot analysis package (Systat Software). Results are depicted as mean ± SEM. 
SI Text
Several cytochrome P450 isozymes oxygenate major polyunsaturated fatty acids to epoxyeicosanoid acids (EpFAs) (1). Most notably, arachidonic acid is converted to four regioisomers of epoxyeicosatrienoic acids by cytochrome P450s (1, 2) . Despite being epoxygenated, the EpFAs are quite stable molecules in the absence of soluble epoxide hydrolase (sEH) activity (1) . The sEH converts these EpFAs to their corresponding vicinal diols, which leads to rapid elimination. The physiological levels of both EpFAs and their degradation products are in the low nanomolar levels in the plasma (Table S1 ). The linoleic acid-derived epoxyoctadecamonoenoic acids (EpOMEs) have 30-to 50-fold higher plasma levels than arachidonic acid-derived epoxyeicosatrienoic acids (EpETrEs), although the physiological significance of this difference is not known. Similarly, the ratio of epoxide to diol for each EpFA species is slightly different (Table S1 ). These differences may stem from differential ability of cytochrome P450 isozymes to synthesize each regioisomer or from differences in secretion or membrane incorporation rates. Despite these subtle differences in the levels of individual EpFA species, inhibition of sEH in vivo has an unequivocal effect of positively modulating the ratio of epoxides to diols (Fig. S5 ). As such, when a panel of 13 EpFAs and 13 corresponding dihydroxy fatty acids are monitored simultaneously, inhibition of sEH increases epoxide to diol ratio across all lipid species, albeit at different efficacy for each one (Table S1 ). At least some of these differences originate from and correlate with the ability of sEH to metabolize each regioisomer, as demonstrated recently (3) .
EpFA metabolites of arachidonic and docosahexaenoic acids have been shown to have antihyperalgesic and antiallodynic properties. Many tissues and cell types have been demonstrated to produce EpFAs, with the liver suspected to be the major systemic source. However, the cell types dominating the local and systemic concentrations of EpFAs have not been conclusively demonstrated. The relevance of plasma EpFA levels to painful conditions, including neuropathic pain, was not examined directly in these experiments and remains to be investigated. However, the plasma EpFAs were quantified as a biomarker of target engagement and Fig. 3A demonstrates that sEH was inhibited throughout the experiments. (4) (5) (6) . All other chemicals and supplies were obtained from Fisher Scientific. Inhibitors of sEH (sEHI) were synthesized and characterized using homogenous, recombinant, affinity-purified rat sEH in our laboratory, as described previously (4, 7).
SI Materials and Methods
Animals. Age-matched male Sprague-Dawley rats weighing 250-300 g were obtained from Charles River Laboratories and maintained on a 12-h light-dark cycle with free access to water and food. All studies were conducted in line with federal regulations and were approved by the Institutional Animal Care and Use Committee at University of California at Davis. Nociceptive measurements were taken at the same time of the day for all groups.
Diabetic Pain Model. Baseline nociceptive thresholds of animals were measured as described below. Immediately after measurement, diabetes was instigated by a single intravenous injection of streptozocin (STZ; 55 mg/kg) as described by Aley and Levine (8) . Blood glucose levels in the morning (7:00-8:00 AM) were measured to confirm hyperglycemia 7-10 d following STZ injection, and mechanical withdrawal thresholds were measured 5-10 d after STZ.
Behavioral Tests and Treatments. Pain behavior was measured using von Frey, Randall-Selitto and modified Hargreaves' tests (9, 10) . Briefly, animals were acclimated to the testing room and the instrument. Before treatment, baseline measurements were taken. For the von Frey test, an electronic anesthesiometer (IITC) with a rigid plastic tip was used. Animals were placed in acrylic cages situated on an elevated steel-mesh screen. The intraplantar region of one hind paw was stimulated three times, with 1-min intervals between each measurement. Force was applied manually until a withdrawal was elicited. The test was conducted using the "MH" mode, giving a readout of the highest applied force in grams. For the Randall-Selitto test, a digital paw pressure Randall-Selitto meter was used (IITC). Animals were manually restrained and the plantar surface of the hind paw was situated on to the flat surface of the apparatus; the tapered end was on the dorsal surface. Force was applied manually until withdrawal was elicited. The test was conducted using the MH mode, giving a readout of the highest force in grams applied to the paw. Prediabetic baseline mechanical withdrawal thresholds varied between 70 and 80 g of force for both tests. The baseline withdrawal thresholds before STZ administration were taken as 100% response and all mean nociceptive thresholds were converted to percentage values. All data are presented as mean ± SE of mean. On the day of the experiments, predrug baseline measurements were taken and inhibitors of sEH were administered after completely dissolving in vehicle PEG400. Gabapentin and morphine were dissolved in saline. All drugs were administered subcutaneously unless otherwise specified.
Metabolic Studies. Glucose was measured in blood collected from the tail using a portable glucometer (Home Aide Diagnostics) For the insulin tolerance test, rats were fasted for 4 h and injected intraperitoneally with 0.75 mU/g body weight human insulin (HumulinR; Eli Lilly). Blood glucose values were measured before and at 15, 30, 45, 60, 90, and 120 min following insulin administration. Serum was collected during the glucose tolerance test at basal, 15, and 30 min postglucose injection and insulin was measured using ELISA using rat insulin as a standard (Crystal Chem). For glucose tolerance tests, rats fasted overnight were injected with 20% (wt/vol) D-glucose at 2 mg/g body weight, and glucose was measured before and at 30, 60, 90, and 120 min following glucose administration. Results are expressed as milligram per deciliter of glucose or nanogram per milliliter of insulin. In metabolic experiments, the sEH inhibitor or vehicle (PEG400) were administered 30 min before bolus glucose or insulin administration.
sEH and Cytochrome P450 Assays. For the sEH and cytochrome P450 assays, liver microsomes, S9, and spinal cord S9 fractions, were used. Diabetic and age-matched control animals were sampled 1 wk following STZ administration (n = 6 per group). Spinal cords were removed by hydraulic extrusion using a 23-gauge needle and cold saline. Microsome and S9 fractions were prepared and the sEH assay was performed, as previously described (7). Protein concentrations were determined using the Bradford assay. For cytochrome P450 assays, microsomes (1 mg/ mL) were mixed with excess substrate (100 μM arachidonic acid) in phosphate buffer containing a premixed NADPH regenerating system (BD Biosciences). The resulting mixture was sampled before incubation for 30 min at 30°C and at the end of the reaction duration. Under these conditions, the product formation remained within the linear range based on the amount of total EpETrE and dihydroxy-5z,8z,11z-eicosatrienoic acid (DiHETrE) production. The reaction was stopped by the addition of same volume of methanol into the tubes. Following centrifugation at 12,000 × g for 5 min, a 10-μL aliquot of this reaction mixture was subjected to LC-MS/MS-based EpETrE and DiHETrE quantification. The results are presented as mean ± SEM of six animals each analyzed once for P450 and sEH activities.
Sampling, Extraction, and Analysis. Eicosanoid analysis was conducted on blood samples collected from the tail vein using a 24-gauge intravenous catheter (BD; Insyte Autoguard). Plasma was separated, frozen, and stored at −80°C until analyses. For spinal cord tissue, treated animals were killed by decapitation under deep anesthesia using isoflurane (5% with 5 L/min oxygen). Immediately after, a coronal cut was performed at proximal to the L6 vertebra of the lumbar cord. Using an 18-gauge needle and saline, tissues were hydraulically extruded with the help of a pump. Intact cords were immediately frozen on dry ice until the tissue-extraction procedure. The subsequent analyses were carried out as described by Yang et al. (11) . Briefly, an internal standard solution containing deuterated standards was added into the samples. This process was followed by extraction of the analytes on a preconditioned solid-phase extraction column (60 mg waters Oasis-HLB; Waters). The eluted samples were evaporated to dryness and reconstituted in 50 μL methanol. A 5-μL aliquot was directly analyzed by LC-ESI-MS/MS. Separation was carried out on a Agilent 1200 SL LC system, using an Agilent Zorbax Eclipse Plus C-18 reversed-phase column (2.1 × 150 mm, 1.8-μM particle size) using a gradient of 0.1% acetic acid as solvent A and 80/15/0.1 acetonitrile/methanol/acetic acid as solvent B. The oxylipins were separated within 21 min using a series of gradients described by Yang et al. (11) . The column was reconditioned for 3.4 min at 35% solvent B before the next sample was introduced. The detection was carried out using a 4000 QTRAP instrument (Applied Biosystems) operating in negative ion mode as previously described by monitoring the selected-reaction monitoring transitions (11) . The limit of quantification (LOQ) of the method was reported previously (11) . We defined LOQ as the quantity of sample required to produce a signal-to-noise ratio of at least 10. Calibration standards had LOQs between 0.07 and 32 pg for the deuteriated analytes. These levels are equivalent to 0.008-4 nM in a volume of 250 μL plasma. A more detailed description of LOQ for each analyte has been recently reported (11) .
Statistical Analyses. Data were analyzed by parametric and nonparametric one-way ANOVA followed by appropriate post hoc tests for between-group comparisons selected by the software suit SigmaPlot analysis package (Systat Software). Results are depicted as mean ± SEM. Regression equations were used for the calculation of potency of inhibitors (IC 50 s). Glucose tolerance test on 16-h-fasted diabetic animals shows no significant difference between treated and control groups (n = 6 per group, one-way ANOVA, P = 0.07). (C) Glucose-stimulated insulin secretion test shows no difference between treated and control groups in both diabetic and normal rats (n = 6 per group, one-way ANOVA, P = 0.15). Blood insulin levels are greatly reduced in type I diabetic rats (STZ vs. non-STZ groups) but this is not augmented by sEHI following glucose administration. (D) Blood glucose levels of nondiabetic rats treated with 3 mg/kg TPAU compared with vehicle controls following insulin administration (n = 4 per group, Kruskal-Wallis one-way ANOVA on Ranks, followed by Dunn's post hoc test P > 0.05). (E) Blood glucose levels of nondiabetic rats treated with vehicle or sEHI following a bolus injection of glucose (n = 4 per group, Kruskal-Wallis one-way ANOVA on Ranks, followed by Dunn's post hoc test P > 0.05). TPAU was administered 30 min before all tests to match the time course of nociceptive assays. . The ratio of epoxy to dihydroxy fatty acids in the spinal cord tissue is reduced by type I diabetes and normalized by inhibition of sEH using TUPS (vehicle n = 3, STZ+vehicle n = 4 and STZ+TUPS n = 6, one-way ANOVA followed by Student Newman-Keuls test, *P = 0.002 vs. vehicle). Table S1 . Quantitative analysis of endogenous oxylipin sEH substrates and products in rat plasma before and after induction of type I diabetes and sEHI (TPAU) administration Sampling of the two diabetic groups was done in a synchronized manner (i.e., 2 wk following STZ). Blood was taken 60 min following treatments [pre-STZ+vehicle (PEG400), n = 6; post-STZ+vehicle, n = 18; post-STZ+TPAU, 3 mg/kg s.c., n = 6]. Oxylipins are grouped based on their parent molecules, linoleic acid, arachidonic acid, docosahexaenoic acid, and eicosapentaenoic acid (first column). The mean and SE of the determined concentration in nanomolars is presented. Ratio of epoxy/ dihydroxy eicosanoids for each epoxide/diol pair is shown in boldface. The SEM for ratios was omitted for clarity. The graphs presented in Fig. 5 include the sum of arachidonic acid, docosahexaenoic acid, and eicosapentaenoic acid metabolites listed here. 
